We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01225302
First Posted: October 21, 2010
Last Update Posted: July 17, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Abbott
  Purpose
The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Secondary objective is to obtain a preliminary efficacy of anti-tumor activity in the subjects as first-line treatment.

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: Linifanib Drug: Carboplatin Drug: Paclitaxel Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Safety (Number of patients with adverse events and/or dose-limiting toxicities) [ Time Frame: At each treatment visit (weekly for 6 weeks, then every 3 weeks) ]
    Evaluation of vital signs, physical exams, clinical lab testing and adverse event monitoring.


Secondary Outcome Measures:
  • Preliminary tumor response [ Time Frame: Week 6 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 12 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 18 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 24 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 30 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 36 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 42 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 48 ]
    Computed Tomography (CT) scan

  • Preliminary tumor response [ Time Frame: Week 54 ]
    Computed Tomography (CT) scan


Enrollment: 12
Study Start Date: September 2010
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A Drug: Linifanib
Low dose linifanib (once a day)
Other Name: ABT-869
Drug: Carboplatin
Given on Day 1 of every 21-day cycle
Other Name: Paraplatin
Drug: Paclitaxel
Given on Day 1 of every 21-day cycle
Other Name: Taxol
Experimental: Arm B Drug: Linifanib
High dose linifanib (once a day)
Other Name: ABT-869
Drug: Carboplatin
Given on Day 1 of every 21-day cycle
Other Name: Paraplatin
Drug: Paclitaxel
Given on Day 1 of every 21-day cycle
Other Name: Taxol

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • The subject must be 20 and older years of age.
  • The subject must have cytologically or histologically confirmed non-squamous NSCLC. Subjects may have a mixed histology but must be predominantly non-squamous to be eligible.
  • The subject must have advanced or metastatic (Stage IV [According to American Joint Committee on Cancer (AJCC) staging manual, 7th edition]) disease that is not amenable to surgical resection or radiation with curative intent.
  • The subject must have not received prior chemotherapy for NSCLC.
  • The subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  • The subject has an Easter Cooperative Oncology Group (ECOG) Performance Score of 0-1.
  • The subject must have adequate bone marrow, renal and hepatic function.

Exclusion Criteria

  • The subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
  • The subject has received any anti-cancer therapy for treatment of NSCLC including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal, "targeted" agents (i.e., erlotinib, imatinib), biologic therapy or cytotoxic chemotherapy (i.e., alkylating agents, microtubule inhibitors, antimetabolites).
  • The subject has a history of another active cancer within the past 5 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous cell or basal cell carcinoma of the skin.
  • The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.
  • The subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.
  • The subject is pregnant or breast feeding.
  • The subject has NSCLC with a predominant squamous cell histology.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01225302


Locations
Japan
Site Reference ID/Investigator# 43502
Osakasayama, Japan
Site Reference ID/Investigator# 43503
Tokyo, Japan
Site Reference ID/Investigator# 43504
Tokyo, Japan
Sponsors and Collaborators
Abbott
Investigators
Study Director: Susumu Matsuki, BS Abbott Japan Co.,Ltd
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Abbott
ClinicalTrials.gov Identifier: NCT01225302     History of Changes
Other Study ID Numbers: W12-076
First Submitted: September 28, 2010
First Posted: October 21, 2010
Last Update Posted: July 17, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action